Water and Salt Balance in Agricultural Lands under Leaching with Shallow Subsurface Drainage Used in Combination with Cut-Drains

Secondary salinization of irrigated lands in drylands is often caused by rising groundwater levels. Open drainage is widely employed to control groundwater. However, salinity levels tend to remain high under malfunctioning drainage conditions. Shallow subsurface drainage may be a possible solution to prevent salt accumulation, although it is difficult for farmers to apply conventional tile drainage systems owing to construction costs. In this regard, we proposed a low-cost shallow subsurface drainage system used in combination with a new mole-drain drilling technology (cut-drain) developed in Japan, whose drainage capacity is similar to tile drain. The aim of this study is to evaluate the effect of the proposed system. The system was installed in a farmland, Uzbekistan. The experimental field was set with/without the system to observe the differences in the balance of water and salt. The results revealed that the remaining infiltrated water in the field decreased by approximately 26% and the removed net mass of salt was 14 Mg ha−1. The direction of salt movement changed from the deeper zone or surrounding field to the open drainage. Therefore, the proposed system can enhance salt removal from fields

令和３年度学生生活研究会実施報告

令和２年度に新型コロナ感染症対策のため開催を見送られた学生生活研究会が令和３年度に再開された。分科会では，令和２年度に行われた新型コロナ感染症への対策を授業関連と学生生活関連に分け総括することで，将来同様の事態が生じた際に備えることとした。また，全体会では，令和４年度に成年年齢が18歳に引き下げられることにより様々な消費者問題が発生することが懸念されることから，この問題の理解を深めるための講演を行った

Tolerability, Efficacy, and Safety of Bisoprolol vs. Carvedilol in Japanese Patients With Heart Failure and Reduced Ejection Fraction - The CIBIS-J Trial -

Background: The comparative tolerability, efficacy, and safety of bisoprolol and carvedilol have not been established in Japanese patients with heart failure and reduced ejection fraction (HFrEF). Methods and Results: The CIBIS-J trial is a multicenter, open-label, non-inferiority randomized controlled trial of bisoprolol vs. carvedilol in 217 patients with HFrEF (EF <= 40%). The primary endpoint was tolerability, defined as reaching and maintaining the maximum maintenance dose (bisoprolol 5 mg/day or carvedilol 20 mg/day) during 48 weeks of treatment. The primary endpoint was achieved in 41.4% of patients in bisoprolol (n=111) and 42.5% in carvedilol (n=106) groups. The non-inferiority of tolerability of bisoprolol compared with carvedilol was not supported, however, neither beta-blocker was superior with regard to tolerability. Heart rate (HR) decreased in both groups and its decrease from baseline was significantly greater in the bisoprolol group (20.3 vs. 15.4 beats/min at 24 week, P<0.05). Plasma B-type natriuretic peptide (BNP) levels decreased in both groups and the decrease was significantly greater in the carvedilol group (12.4 vs. 39.0 % at 24 weeks, P<0.05). Conclusions: There were no significant differences between bisoprolol and carvedilol in the tolerability of target doses in Japanese HFrEF patients. The clinical efficacy and safety were also similar despite the greater reduction in HR by bisoprolol and plasma BNP by carvedilol